Vascular endothelial growth factor (VEGF) mediates endothelial cell mitogenesis and enhances vascular permeability. VEGF interacts with the endothelium via two membrane-spanning receptors, fms-like tyrosine kinase (Flt)-1 and kinase domain receptor. A soluble form of Flt-1 (sFlt-1) was isolated from endothelial cell media ; however, its biological significance is still unknown, with limited data on plasma sFlt-1 levels in disease states. We have developed two new ELISAs for detecting free and VEGF-complexed sFlt-1, which were tested in accordance with standard validation and assessment methodologies employed in commercial settings. The intraand inter-assay coefficients of variation are 5 % and 10 % respectively, and results are highly reproducible. Applying these ELISAs in a clinical setting, we measured levels of VEGF, free and complexed sFlt-1 in citrated plasma from 40 patients with cardiovascular disease and 40 healthy controls. Median (interquartile range) plasma levels of VEGF in patients were significantly greater than controls [403 pg/ml (158-925 pg/ml) versus 113 pg/ml (33-231 pg/ml), P 0.05]. Free sFlt-1 was significantly lower in patients compared with controls [8 ng/ml (2-22 ng/ml) versus 21 ng/ml (10-73 ng/ml), P 0.05]. There was no significant difference in the levels of complexed sFlt-1 between the two groups. Plasma levels of VEGF-complexed sFlt-1 are minimal, despite the presence of excess free sFlt-1. Thus unbound plasma VEGF detected by ELISA may represent the majority of circulating VEGF, and justifies the measurement of plasma VEGF as an indicator of circulating VEGF levels. Furthermore, these results suggest that circulating sFlt-1 may serve as a selective inhibitor of VEGF activity, and that this regulatory mechanism may be altered by pathological conditions.
INTRODUCTION
Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis, is involved in vascular remodelling following physiological repair and regener-Flt-1 (sFlt-1) was initially isolated from human umbilical vessel endothelial cell culture medium [4] ; however, this form of the receptor is also thought to be present in amniotic fluids [5] .
In cancer increased production of VEGF (mRNA or circulating) has been shown to directly contribute to disease progress by aiding the spread of tumour cells [6] [7] [8] . However, in other diseases, such as cardiovascular disorders, the role of VEGF is not clearly defined. Few studies have examined the possible relationship between circulating levels of VEGF and disease severity and\or progression [9, 10] . Nevertheless, overproduction of VEGF, as reflected in the plasma, is always associated with pathology. In cardiovascular disease (CVD), for example, hypoxia due to atherosclerotic narrowing of the arterial lumen may lead to increased angiogenesis, partly mediated by VEGF. Indeed, increased angiogenic activity in the media of large atherosclerotic arteries compared with normal arteries suggests that VEGF-mediated angiogenesis may be an ongoing process in atherosclerosis [11] .
The release of VEGF by platelets during activation has been shown to influence VEGF levels in serum, giving rise to speculation about the validity and interpretation of studies based on serum samples [12, 13] . Several studies have reported raised levels of VEGF in serum and plasma from patients with cancer [9, 10, 14] , but studies reporting levels of VEGF in patients with CVD are limited, and have focused on serum rather than plasma [15, 16] . Most VEGF ELISA systems detect and quantify unbound circulating VEGF alone and do not allow for VEGF complexed to sFlt-1 (total plasma VEGF). Indeed, the presence of sFlt-1 in serum samples significantly reduces the detectable levels of VEGF ELISA in a dose-response manner [13] .
In view of these interactions, we have developed two novel sFlt-1 ELISA systems : one capable of detecting sFlt-1 complexed to VEGF and another defining unbound sFlt-1 which is able to bind exogenous recombinant VEGF-165 using commercially available antibodies. The newly developed ELISA systems have inter-and intra-assay coefficients of variation less than 10 % and 5 % respectively. A third ELISA that had been previously developed was used to detect circulating VEGF. We applied these ELISAs to measure levels of VEGF, and free and complexed sFlt-1 in citrated plasma samples from healthy controls and patients with CVD.
METHODS

Antibodies and recombinant proteins
Rabbit anti-human VEGF, biotinylated goat anti-human VEGF, monoclonal anti-human Flt-1 and biotinylated goat anti-human Flt-1 antibodies, recombinant VEGF-165 and Flt-1\Fc chimaera proteins were all purchased from R & D Systems (Abingdon, Oxfordshire, U.K.).
Subjects
Venous blood was collected from an antecubital fossa vein of the left or right arm into trisodium citrated tubes, using 21 gauge multi-drawing needles, from 40 healthy controls (25 men, mean age 60p14 years) and 40 patients with CVD (29 men, mean age 61p11 years). These patients had peripheral artery disease (critical limb ischaemia or atheromatous disease verified in the iliac, femoral or popliteal arteries by angiography and standard B mode Doppler\ultrasound imaging and\or an ankle\ brachial pressure index 0.85), accompanied by other forms of CVD, including essential hypertension [blood pressure consistently above 160\90 mmHg (n l 13)], ischaemic heart disease and\or previous myocardial infarction characterized by ECG changes and raised levels of creatinine kinase 150 units\ml (n l 12), and strokes diagnosed by head computer tomography scan (n l 4). Five of the 40 patients had undergone coronary arterial graft bypass surgery. Whole blood was centrifuged at 600 g at 4 mC for 20 min, and citrated plasma samples were aliquoted into clean tubes before measuring levels of VEGF, and free and complexed sFlt-1. Subjects with abnormal platelet count (normal range 150-400i10*\l), cancer, inflammatory disease or diabetes, and those on prescribed medication such as steroids, immunosuppressants, cytotoxic agents, vasopressin, hormone replacement therapy and warfarin, were excluded.
Development of free and complexed sFlt-1 ELISA assays
The ELISA systems were based on receptor-ligand chemistry of the receptor (Flt-1). Both ELISA systems are modified double-sandwich non-competitive ELISAs. The free sFlt-1 ELISA consisted of a polyclonal antihuman VEGF antibody (capture antibody) and biotinylated goat anti-human Flt-1 as the detection antibody. The complexed sFlt-1 ELISA consisted of a monoclonal anti-human Flt-1 antibody (capture antibody) and biotinylated goat anti-human VEGF as the detection antibody. Each experiment described was repeated three times and the values shown in the tables are the means of the three experiments.
Optimizing concentrations of anti-VEGF antibodies for VEGF and sFlt-1 ELISAs
Initially, rabbit anti-human VEGF antibody (capture antibody for the free sFlt-1 ELISA), at concentrations ranging from 0.5 µg\ml to 5 µg\ml, was adsorbed on to 96-well microtitre immunoassay plates for a minimum of 15 h at 4 mC. Biotinylated goat anti-VEGF antibody (detection antibody for the complexed sFlt-1 ELISA), at Development and application of immunoassays for soluble VEGF receptor sFlt-1 Detection Ab concn. 750 ng/ml 750 ng/ml 750 ng/ml 750 ng/ml 750 ng/ml concentrations ranging from 250 ng\ml to 750 ng\ml, were combined to measure plasma VEGF and to determine the optimum concentrations for the sFlt-1 ELISA systems. Standard curves were generated using recombinant VEGF (rhVEGF)-165. Results of this study are shown in Table 1 .
Optimizing concentrations of monoclonal anti-Flt-1 antibody for complexed sFlt-1 ELISA
Three different concentrations (1, 4 and 5 µg\ml) of monoclonal anti-human Flt-1 were used as capture antibody to determine the optimum concentration for the complexed sFlt-1 ELISA. Recombinant Flt-1\Fc chimaera standards, at concentrations ranging from 10 pg\ml to 500 ng\ml, diluted in 250 ng\ml of rhVEGF-165, was used to generate standard curves, and biotinylated anti-human VEGF antibody was used as detection antibody. This mixture of recombinant proteins ensured binding to the capture and detection antibodies. Results are displayed in Table 2 .
Optimizing concentrations of anti-human biotinylated Flt-1 antibody for free sFlt-1 ELISA
These series of experiments were designed to optimize the concentration of the detection antibody (biotinylated goat anti-human Flt-1) able to detect rhFlt-1\Fc bound to immobilized rhVEGF-165 (250 ng\ml). Plates were coated with rabbit anti-human VEGF at 4 µg\ml, as determined from previous experiments. This antibody was then saturated with rhVEGF-165 for 2 h. Recombinant Flt-1\Fc chimaera standards (10 pg\ml to 500 ng\ml) were used to generate standard curves, and biotinylated goat anti-human Flt-1, at concentrations ranging from 100 ng\ml to 750 ng\ml, was used to detect rhFlt-1\Fc bound to immobilized rhVEGF (Table 3) .
Validation of specificity of the free sFlt-1 ELISA
To confirm that the Flt-1\Fc chimaera binds to rhVEGF-165 immobilized on to the solid-phase, inhibition assays were carried out. This involved saturating immobilized 
Protocol for VEGF ELISA
Levels of VEGF were determined by ELISA using a previously described protocol [17] . Briefly, plates were coated with 4 µg\ml rabbit anti-VEGF antibody, then washed and blocked before adding samples or rhVEGF-165 standards in duplicates. Biotinylated goat anti-VEGF antibody was used to detect bound VEGF and ExtrAvidin-peroxidase was added to amplify the antibody-antigen reaction. Colour was developed using o-phenylenediamine dihydrochloride tablets (Sigma) and absorbance was read at a wavelength of 492 nm.
Statistical methods
In the clinical study, data for VEGF and sFlt-1 are nonparametrically distributed and are presented as median (interquartile range). Comparisons between cases and controls were calculated using the Mann-Whitney test. All statistical analyses were performed using Minitab version 11 for Windows (Minitab Inc., State College, PA, U.S.A.). P values 0.05 were considered statistically significant.
RESULTS
Validation of specificity of the free sFlt-1 ELISA
At all three concentrations of the rhVEGF-165 (125 ng\ml, 250 ng\ml and 500 ng\ml) binding to Inhibition assay using biotinylated anti-VEGF to detect immobilized rhVEGF-165 (250 ng/ml) in the presence of rhFlt-1/Fc chimaera at varying concentrations (*). Portion of a typical standard curve for free sFlt-1 ELISA using biotinylated antiFlt-1 to detect rhFlt-1/fc chimaera bound to immobilized rhVEGF-165 (5).
biotinylated anti-VEGF (detection antibody) was inhibited by the rhFlt-1\Fc chimaera in a dose-response manner, as shown in Table 4 and Figure 1 . The highest concentration of rhFlt-1\Fc chimaera (250 ng\ml) resulted in the lowest absorbance values, even with 500 ng\ml of rhVEGF-165. Conversely, in the absence of rhFlt-1\Fc (i.e assay buffer alone), the absorbance values gradually increased from 125 ng\ml to 500 ng\ml of the rhVEGF. This confirms that rhFlt-1\Fc chimaera is able to bind the rhVEGF-165 immobilized on to the capture antibody, and can consequently inhibit the detection of rhVEGF-165 by biotinylated anti-VEGF (detection antibody) in a dose-dependent manner.
Intra-and inter-assay coefficients of variation
The precision of the assays was determined by calculating the intra-and inter-assay coefficients of variation for each of the ELISA systems. The intra-and inter-assay coefficients of variation are obtained by measuring the variation within an individual assay and between different assays respectively. Three different samples, pooled human plasma, tissue culture supernatant from human aortic smooth muscle cells and human umbilical vein endothelial cells, were used. Typically, the intra-and inter-assay coefficients of variation for an ELISA should be less than 5 % and 10 % respectively [18] . The intraassay coefficients of variation were calculated from the results of 34 measurements from single plates, whereas the inter-assay coefficients of variation were calculated from the results of 51 individual assays for each ELISA developed. Intra-and inter-assay coefficients for the ELISA system are displayed in Table 5 .
Final protocol for free sFlt-1 ELISA
Initially, 96-well microtitre immunoassay plates (Dynex Labsystems, Ashford, Middlesex) were coated with 4 µg\ml rabbit anti-VEGF in 0.05 M carbonate buffer (pH 9.6) for a minimum of 15 h at 4 mC (100 µl\well). The plates were washed five times in assay buffer (0.05 % Tween 20 in 0.1 M PBS, pH 7.2), before and after blocking for 2 h (as determined from previous experiments ; results not shown) at room temperature with 5 % dried powdered milk (Marvel4) in PBS-Tween. The plates were then saturated with 250 ng\ml rhVEGF-165 for an additional 2 h. Recombinant Flt-1\Fc chimaera standards [ranging from 10 pg to 500 ng\ml (100 µl\ well), including zero, i.e assay buffer only] were added to the immobilized rhVEGF and left for 2 h. Detection antibody, biotinylated goat anti-human Flt-1 at 500 ng\ ml (100 µl\well), was added and the plates were left for a further 2 h at room temperature. ExtrAvidin-peroxidase (1 : 1000 dilution) was added (100 µl\well), and plates were incubated at room temperature for 45 min. Following the incubation period, plates were washed five times and colour was developed using substrate o-phenylenediamine dihydrochloride tablets dissolved in 0.05 M citrate buffer (pH 5.0). The reaction was stopped using 1 M HCl and the absorbance was read immediately at 492 nm. This assay has a lower limit of sensitivity of 50 pg\ml.
Final protocol for complexed sFlt-1 ELISA
Monoclonal anti-human Flt-1 (4 µg\ml) in 0.05 M carbonate buffer was adsorbed on to 96-well microtitre immunoassay plates for a minimum of 15 h at 4 mC. The plates were washed and blocked, as previously described, and rhFlt-1\Fc standards diluted in 250 ng\ml of Typical standard curves for VEGF ELISA using anti-VEGF capture and detection antibodies (j), and typical standard curves for sFlt-1-complexed VEGF ELISA using monoclonal anti-Flt-1 as the capture antibody and anti-VEGF as the detection antibody ( ). Recombinant VEGF-165 was used for the VEGF ELISA and rhFlt-1/Fc chimaera (diluted in 250 ng/ml rhVEGF-165) was used for the VEGF-complexed ELISA.
rhVEGF-165 (ranging from 10 pg\ml to 500 ng\ml and zero) were added before incubating plates for 2 h at room temperature. Plates were washed five times in assay buffer and biotinylated goat anti-human VEGF (500 ng\ml) was added before incubating the plates for another 2 h at room temperature. ExtrAvidin-peroxidase (1 : 1000 dilution) was added, and plates were incubated at room temperature for 45 min. Following the incubation period plates were washed five times, and colour was developed using substrate o-phenylenediamine dihydrochloride tablets dissolved in 0.05 M citrate buffer with hydrogen peroxide. The reaction was stopped using 1 M HCl, and the absorbance was read immediately at 492 nm. This assay has a lower limit of sensitivity of 10 pg\ml. Since the capture antibody binds the receptor Bars represent median values displayed in Table 6 . Levels of VEGF (pg/ml) are displayed on a log scale.
portion (sFlt-1) and the detection antibody binds the ligand (VEGF), the standard curve consists of a mixture of recombinant VEGF and Flt-1\Fc chimaera with the Development and application of immunoassays for soluble VEGF receptor sFlt-1
Figure 4 Levels of free sFlt-1 in controls and patients with CVD
Bars represent median values displayed in Table 6 . Levels of free sFlt-1 (ng/ml) are displayed on a log scale.
concentration of the VEGF remaining constant at 250 ng\ml ( Figure 2 ). Bars represent median values displayed in Table 6 . Levels of VEGF-complexed sFlt-1 (pg/ml) are displayed on a log scale.
Measurement of VEGF and sFlt-1 in patients with CVD and in healthy controls
DISCUSSION
Levels of VEGF in citrated plasma from patients with CVD were significantly elevated, whereas that of free sFlt-1 were lower compared with healthy controls. However, in both the controls and patients, a large difference was observed in the levels of VEGF compared with that of free sFlt-1. At the pg\ng level, the amount of free plasma sFlt-1 from the controls is 186-fold greater than that of VEGF. Taking the relative molecular mass of VEGF to be 45 kDa [19] and that of free sFlt-1 to be about 100 kDa [3] , then the molarity of sFlt-1 still exceed that of VEGF by approx. 74 in these subjects, since one molecule of VEGF is thought to bind stochiometrically to one molecule of sFlt-1 [3, 20, 21] . This molar ratio is doubled if receptor dimerization occurs upon ligand binding. Therefore whether the difference between free sFlt-1 and VEGF is estimated in pg\ng or molar concentrations, it is clear that the amount of free sFlt-1 in citrated plasma greatly surpass that of VEGF. In contrast, only very low levels of VEGF-complexed sFlt-1 were observed in both study groups. One plausible explanation for the low plasma levels of complexed sFlt-1 might be receptor dimerization, owing to the fact that one molecule of sFlt-1 is able to bind a single subunit of VEGF or the homodimer to form a receptor-ligand complex [3] . Receptor dimerization upon binding of a dimeric ligand is a common occurrence with several tyrosine kinase receptors [22] [23] [24] . The binding of a dimeric ligand to its receptor can promote dimerization, which may increase the stability of the receptor-ligand complex, the ligand itself or induce structural\ configuration changes which are required to initiate a signalling cascade [25] . Assuming that sFlt-1 complexes VEGF with the same high affinity and dissociation constants as the membrane-spanning receptor, it is possible that this particular ELISA is unable to detect dimeric sFlt-1 molecules bound to VEGF for stochiometric or configurational reasons. These points may partly explain the excess of free unbound sFlt-1 compared with complexed sFlt-1. This theory is given further credence by the observation that prolonged storage of whole blood leads to an increase in levels of VEGF and free sFlt-1 in the resultant plasma, which is possibly due to the release of receptor-bound VEGF and dissociation of bound receptor homodimers over extended periods of time (results not shown). sFlt-1 has been shown to form heterodimers with membrane-bound Flt-1 and kinase domain receptor, thus abolishing their signal transduction by acting as a dominant negative inhibitor in vitro [3, 4] . This implies that the production of sFlt-1 may represent a biological mechanism for selectively and efficiently inhibiting VEGF activity.
The data pertaining to human plasma presented in the present paper support the existence of such a regulatory system. The difference between plasma levels of VEGF and free sFlt-1 in healthy controls is greater than 100-fold, whereas, in patients, this difference is less than 20-fold. It is conceivable that physiological levels of VEGF are very low, and limiting its production, having a relatively short half-life and production of excess sFlt-1, which acts in an inhibitory manner, stringently controls the activity of this growth factor. Therefore the onset of pathophysiological conditions may induce aberrant production of growth factors such as VEGF. In cancer, for example, strong correlations have been observed between the degree of vascularization and VEGF expression [10, 26, 27] , but the mechanism for the increased production of VEGF, or the catalyst for the initiation of this process, is yet to be elucidated. In the patients with CVD, raised plasma VEGF may be the result of overproduction and the altered ratio between plasma levels of sFlt-1 and VEGF, resulting in an imbalance of the ' physiological equilibrium ' between VEGF and sFlt-1.
In summary, we have developed two novel assays for the measurement of plasma levels of free and complexed VEGF receptor, sFlt-1. Plasma levels of VEGF-complexed sFlt-1 are minimal, despite the presence of excess free sFlt-1, and justify the measurement of plasma VEGF as an indicator of circulating VEGF levels. Furthermore, circulating sFlt-1 may serve as a selective inhibitor of VEGF activity, and this regulatory mechanism may be altered by pathological conditions. A better understanding of the role of these circulating molecules would enhance our knowledge of angiogenesis and possibly contribute to the treatment of CVD.
